Tiny leg implant drug levels tracked in 7 patients

NCT ID NCT05208905

Ongoing Knowledge-focused Sponsor: Abbott Medical Devices Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks how much of a drug called everolimus enters the blood after placing a special coated device (Esprit BTK) in leg arteries of people with severe blocked leg circulation (critical limb ischemia). About 7 participants will have blood samples taken over 60 days. The goal is only to measure drug levels, not to treat the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRITICAL LIMB ISCHEMIA (CLI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Limb-Threatening Ischemia limb ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRITICAL LIMB ISCHEMIA (CLI)

Contacts and locations

Show contact details

Locations

Ascension St. John Jane Phillips

Bartlesville, Oklahoma, 74006, United States
Charlton Memorial Hospital

South Dartmouth, Massachusetts, 02747, United States
First Coast Cardiovascular Institute

Jacksonville, Florida, 32256, United States
National Taiwan University Hospital

Taipei, Taiwan
Sir Charles Gairdner Hospital

Nedlands, WAUS, Australia